Immune therapy and targeted therapy for rare kidney cancers
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs—an immunotherapy called toripalimab and a targeted therapy called axitinib—for people with rare kidney cancers that have spread. The goal is to see if this combination can shrink or control the cancer before any surgery to remove the kidney.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You must have a type of kidney cancer called non-clear cell renal cell carcinoma or renal medullary carcinoma that has spread to other parts of the body
- You must not have received any prior treatment for the cancer that has spread
- You must have at least one tumor outside the kidney that can be measured on a scan
- A biopsy of your kidney tumor must show a specific marker called TLS (tertiary lymphoid structures), which indicates immune cells in the tumor
- You must be in good enough health to care for yourself and do light activities
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs — an immunotherapy (toripalimab) and a targeted therapy (axitinib) — as the first treatment for advanced kidney cancer. The approach may shrink the tumor before deciding whether and when to remove the kidney surgically.
This trial tests a combination of immunotherapy and targeted drugs (called IO/TKI) given before and after surgery for clear cell renal cell carcinoma (a type of kidney cancer). The goal is to shrink tumors and improve survival outcomes.
This trial tests if a combination of targeted embolization, immunotherapy (Toripalimab), and a targeted therapy pill (Axitinib) can shrink advanced kidney cancer before surgery. It is for patients whose cancer has spread to nearby tissues or lymph nodes, or has limited spread elsewhere that can be removed.
This trial tests a combination of targeted radiation, an oral drug (axitinib), and an immunotherapy (toripalimab) for people with kidney cancer that has spread to a few spots. It aims to see if this combo helps control the cancer longer.
This trial tests a combination of targeted therapy (axitinib) and immunotherapy (toripalimab) alongside stereotactic body radiation therapy (SBRT) for kidney cancer that has come back or spread. It may be an option if you have a limited number of metastatic tumors that can be treated with radiation.
This trial tests a new drug (JS004) combined with an existing immunotherapy (toripalimab) for kidney cancer that has progressed after previous immunotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Hear when a new Metastatic Non-Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.